Published in Mol Pharmacol on June 18, 2007
Nuclear receptors in the multidrug resistance through the regulation of drug-metabolizing enzymes and drug transporters. Biochem Pharmacol (2012) 1.31
PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics. Pharmacogenomics (2008) 1.27
Minireview: Not picking pockets: nuclear receptor alternate-site modulators (NRAMs). Mol Endocrinol (2009) 1.25
Alleviation of gut inflammation by Cdx2/Pxr pathway in a mouse model of chemical colitis. PLoS One (2012) 1.14
Evolution of pharmacologic specificity in the pregnane X receptor. BMC Evol Biol (2008) 1.14
A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. Drug Metab Dispos (2008) 1.14
Overcoming drug resistance by regulating nuclear receptors. Adv Drug Deliv Rev (2010) 1.10
The structural basis of pregnane X receptor binding promiscuity. Biochemistry (2009) 1.09
Novel inhibitors of human organic cation/carnitine transporter (hOCTN2) via computational modeling and in vitro testing. Pharm Res (2009) 1.09
Elucidating the 'Jekyll and Hyde' nature of PXR: the case for discovering antagonists or allosteric antagonists. Pharm Res (2009) 1.09
Ligand specificity and evolution of liver X receptors. J Steroid Biochem Mol Biol (2008) 1.06
Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. Antimicrob Agents Chemother (2008) 1.06
Essential metabolites of Mycobacterium tuberculosis and their mimics. MBio (2011) 1.04
Targeting xenobiotic receptors PXR and CAR in human diseases. Drug Discov Today (2014) 1.04
PXR antagonists and implication in drug metabolism. Drug Metab Rev (2013) 1.03
In vivo and in vitro characterization of a first-in-class novel azole analog that targets pregnane X receptor activation. Mol Pharmacol (2011) 1.01
Challenges predicting ligand-receptor interactions of promiscuous proteins: the nuclear receptor PXR. PLoS Comput Biol (2009) 1.01
Machine learning methods and docking for predicting human pregnane X receptor activation. Chem Res Toxicol (2008) 0.99
Ligand promiscuity of aryl hydrocarbon receptor agonists and antagonists revealed by site-directed mutagenesis. Mol Cell Biol (2014) 0.94
Novel yeast-based strategy unveils antagonist binding regions on the nuclear xenobiotic receptor PXR. J Biol Chem (2013) 0.93
Post-translational and post-transcriptional modifications of pregnane X receptor (PXR) in regulation of the cytochrome P450 superfamily. Curr Drug Metab (2013) 0.90
Improving integrative searching of systems chemical biology data using semantic annotation. J Cheminform (2012) 0.89
Camptothecin attenuates cytochrome P450 3A4 induction by blocking the activation of human pregnane X receptor. J Pharmacol Exp Ther (2010) 0.89
Open Source Bayesian Models. 1. Application to ADME/Tox and Drug Discovery Datasets. J Chem Inf Model (2015) 0.88
Hybrid scoring and classification approaches to predict human pregnane X receptor activators. Pharm Res (2008) 0.88
Human immunodeficiency virus protease inhibitors interact with ATP binding cassette transporter 4/multidrug resistance protein 4: a basis for unanticipated enhanced cytotoxicity. Mol Pharmacol (2013) 0.87
Identification of novel activators of constitutive androstane receptor from FDA-approved drugs by integrated computational and biological approaches. Pharm Res (2012) 0.86
Current industrial practices in assessing CYP450 enzyme induction: preclinical and clinical. AAPS J (2008) 0.85
Oxygenated polyketides from Plakinastrella mamillaris as a new chemotype of PXR agonists. Mar Drugs (2013) 0.85
A substrate pharmacophore for the human organic cation/carnitine transporter identifies compounds associated with rhabdomyolysis. Mol Pharm (2012) 0.82
Modulation of xenobiotic receptors by steroids. Molecules (2013) 0.82
Understanding nuclear receptors using computational methods. Drug Discov Today (2009) 0.80
Evaluation of computational docking to identify pregnane X receptor agonists in the ToxCast database. Environ Health Perspect (2010) 0.80
Pregnane X receptor and drug-induced liver injury. Expert Opin Drug Metab Toxicol (2014) 0.79
Pharmacophore and 3D-QSAR characterization of 6-arylquinazolin-4-amines as Cdc2-like kinase 4 (Clk4) and dual specificity tyrosine-phosphorylation-regulated kinase 1A (Dyrk1A) inhibitors. J Chem Inf Model (2013) 0.79
Pharmacophore mapping based inhibitor selection and molecular interaction studies for identification of potential drugs on calcium activated potassium channel blockers, tamulotoxin. Pharmacogn Mag (2013) 0.79
Role of pregnane X receptor and aryl hydrocarbon receptor in transcriptional regulation of pxr, CYP2, and CYP3 genes in developing zebrafish. Toxicol Sci (2014) 0.78
Differential regulation of CYP3A4 promoter activity by a new class of natural product derivatives binding to pregnane X receptor. Biochem Pharmacol (2013) 0.78
Small-molecule modulators of PXR and CAR. Biochim Biophys Acta (2016) 0.78
Targeting nuclear receptors with marine natural products. Mar Drugs (2014) 0.77
Marine and semi-synthetic hydroxysteroids as new scaffolds for pregnane X receptor modulation. Mar Drugs (2014) 0.76
Exploration of the conformational landscape in pregnane X receptor reveals a new binding pocket. Protein Sci (2016) 0.75
Binary and ternary combinations of anti-HIV protease inhibitors: effect on gene expression and functional activity of CYP3A4 and efflux transporters. Drug Metabol Drug Interact (2014) 0.75
A concentration addition model to assess activation of the pregnane X receptor (PXR) by pesticide mixtures found in the French diet. Toxicol Sci (2014) 0.75
Development and validation of a genetic algorithm for flexible docking. J Mol Biol (1997) 14.36
An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell (1998) 5.97
The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest (1998) 4.76
The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc Natl Acad Sci U S A (2001) 4.58
SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev (1998) 4.19
The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med (2001) 3.45
The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science (2001) 3.27
Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci U S A (1998) 3.24
Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell (2002) 3.13
Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662. Biochemistry (2002) 2.97
St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci U S A (2000) 2.64
P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR. Arch Biochem Biophys (1999) 2.21
Highly chlorinated PCBs inhibit the human xenobiotic response mediated by the steroid and xenobiotic receptor (SXR). Environ Health Perspect (2004) 2.16
Comparison of alamar blue and MTT assays for high through-put screening. Toxicol In Vitro (2004) 2.06
CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos (2002) 1.94
Coordinate regulation of xenobiotic and bile acid homeostasis by pregnane X receptor. Drug Metab Dispos (2001) 1.70
Coactivator binding promotes the specific interaction between ligand and the pregnane X receptor. J Mol Biol (2003) 1.57
2.1 A crystal structure of human PXR in complex with the St. John's wort compound hyperforin. Biochemistry (2003) 1.55
Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. Mol Pharmacol (2001) 1.53
The dietary isothiocyanate sulforaphane is an antagonist of the human steroid and xenobiotic nuclear receptor. Mol Pharmacol (2006) 1.47
Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole. Oncogene (2006) 1.40
Interaction of transcriptional intermediary factor 2 nuclear receptor box peptides with the coactivator binding site of estrogen receptor alpha. J Biol Chem (2002) 1.35
Induction of drug metabolism by forskolin: the role of the pregnane X receptor and the protein kinase a signal transduction pathway. J Pharmacol Exp Ther (2004) 1.33
Evolution of the pregnane x receptor: adaptation to cross-species differences in biliary bile salts. Mol Endocrinol (2005) 1.33
In vitro and pharmacophore-based discovery of novel hPEPT1 inhibitors. Pharm Res (2005) 1.30
The phytoestrogen coumestrol is a naturally occurring antagonist of the human pregnane X receptor. Mol Endocrinol (2007) 1.29
Crystal structure of the pregnane X receptor-estradiol complex provides insights into endobiotic recognition. Mol Endocrinol (2007) 1.25
Peptide mimetic HIV protease inhibitors are ligands for the orphan receptor SXR. J Biol Chem (2001) 1.20
Crystal structure of the PXR-T1317 complex provides a scaffold to examine the potential for receptor antagonism. Bioorg Med Chem (2006) 1.19
Traditional Chinese medicines Wu Wei Zi (Schisandra chinensis Baill) and Gan Cao (Glycyrrhiza uralensis Fisch) activate pregnane X receptor and increase warfarin clearance in rats. J Pharmacol Exp Ther (2005) 1.19
Pharmacophore-based discovery of ligands for drug transporters. Adv Drug Deliv Rev (2006) 1.15
Bisphenol-A, an environmental estrogen, activates the human orphan nuclear receptor, steroid and xenobiotic receptor-mediated transcription. Eur J Endocrinol (2001) 1.15
Evaluation of 170 xenobiotics as transactivators of human pregnane X receptor (hPXR) and correlation to known CYP3A4 drug interactions. Curr Drug Metab (2006) 1.13
Endocrine disrupting chemicals, phthalic acid and nonylphenol, activate Pregnane X receptor-mediated transcription. Mol Endocrinol (2000) 1.13
Activated pregnenolone X-receptor is a target for ketoconazole and its analogs. Clin Cancer Res (2007) 1.12
Use of the nuclear receptor PXR to predict drug interactions. Toxicology (2000) 1.12
A ligand-based approach to understanding selectivity of nuclear hormone receptors PXR, CAR, FXR, LXRalpha, and LXRbeta. Pharm Res (2002) 1.10
Tocotrienols activate the steroid and xenobiotic receptor, SXR, and selectively regulate expression of its target genes. Drug Metab Dispos (2004) 1.09
PXR-dependent induction of human CYP3A4 gene expression by organochlorine pesticides. Biochem Pharmacol (2002) 1.07
Putative role of the orphan nuclear receptor SXR (steroid and xenobiotic receptor) in the mechanism of CYP3A4 inhibition by xenobiotics. J Biol Chem (2002) 1.06
Pregnane X receptor prevents hepatorenal toxicity from cholesterol metabolites. Proc Natl Acad Sci U S A (2005) 1.06
A pharmacophore for human pregnane X receptor ligands. Drug Metab Dispos (2002) 1.03
Structural insights into the promiscuity and function of the human pregnane X receptor. Curr Opin Drug Discov Devel (2002) 1.03
Activation of the steroid and xenobiotic receptor (human pregnane X receptor) by nontaxane microtubule-stabilizing agents. Clin Cancer Res (2005) 1.01
A combined approach to drug metabolism and toxicity assessment. Drug Metab Dispos (2005) 1.00
PXR and the regulation of apoA1 and HDL-cholesterol in rodents. Pharmacol Res (2004) 0.98
Pharmacophore modeling and in silico screening for new P450 19 (aromatase) inhibitors. J Chem Inf Model (2006) 0.98
In silico prediction of pregnane X receptor activators by machine learning approaches. Mol Pharmacol (2006) 0.98
Calcium channel modulators of the dihydropyridine family are human pregnane X receptor activators and inducers of CYP3A, CYP2B, and CYP2C in human hepatocytes. Drug Metab Dispos (2001) 0.96
A PXR reporter gene assay in a stable cell culture system: CYP3A4 and CYP2B6 induction by pesticides. Biochem Pharmacol (2004) 0.95
Ligands have various potential effects on the degradation of pregnane X receptor by proteasome. Endocrinology (2002) 0.93
Use of a reporter gene assay to predict and rank the potency and efficacy of CYP3A4 inducers. Drug Metab Dispos (2001) 0.92
A pregnane X receptor agonist with unique species-dependent stereoselectivity and its implications in drug development. Mol Pharmacol (2005) 0.92
Structural diversities of active site in clinical azole-bound forms between sterol 14alpha-demethylases (CYP51s) from human and Mycobacterium tuberculosis. J Biol Chem (2004) 0.91
In silico tools to aid risk assessment of endocrine disrupting chemicals. Toxicology (2004) 0.90
Three-dimensional quantitative structure-activity relationship analysis of human CYP51 inhibitors. Drug Metab Dispos (2006) 0.89
Correlation of high-throughput pregnane X receptor (PXR) transactivation and binding assays. J Biomol Screen (2004) 0.89
Carotenoids and their metabolites are naturally occurring activators of gene expression via the pregnane X receptor. Eur J Nutr (2004) 0.86
The endocrine disrupting chemical, diethylhexyl phthalate, activates MDR1 gene expression in human colon cancer LS174T cells. J Endocrinol (2006) 0.84
Promiscuous regulator of xenobiotic removal. Nat Med (2001) 0.82
Induction of PXR-mediated metabolism by beta-carotene. Biochim Biophys Acta (2004) 0.81
Structural model reveals key interactions in the assembly of the pregnane X receptor/corepressor complex. Mol Pharmacol (2006) 0.80
Membrane transporters in drug development. Nat Rev Drug Discov (2010) 8.56
Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res (2003) 3.72
Educating medical students in laboratory medicine: a proposed curriculum. Am J Clin Pathol (2010) 3.18
Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science (2010) 2.99
Endocytic mechanisms for targeted drug delivery. Adv Drug Deliv Rev (2007) 2.38
Highly chlorinated PCBs inhibit the human xenobiotic response mediated by the steroid and xenobiotic receptor (SXR). Environ Health Perspect (2004) 2.16
TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J Clin Oncol (2004) 2.09
A phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid malignancies. Clin Cancer Res (2009) 2.01
CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos (2002) 1.94
Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032). Antimicrob Agents Chemother (2012) 1.85
Bisphenol A and its analogues activate human pregnane X receptor. Environ Health Perspect (2012) 1.81
Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study. J Clin Oncol (2003) 1.79
Lack of androgenicity and estrogenicity of the three monomers used in Eastman's Tritan™ copolyesters. Food Chem Toxicol (2012) 1.76
Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol (2008) 1.69
Rapid identification of P-glycoprotein substrates and inhibitors. Drug Metab Dispos (2006) 1.68
Online chemical modeling environment (OCHEM): web platform for data storage, model development and publishing of chemical information. J Comput Aided Mol Des (2011) 1.68
Molecular basis of vitamin E action: tocotrienol modulates 12-lipoxygenase, a key mediator of glutamate-induced neurodegeneration. J Biol Chem (2003) 1.61
Transport of poly(amidoamine) dendrimers across Caco-2 cell monolayers: Influence of size, charge and fluorescent labeling. Pharm Res (2006) 1.51
Identification of interactive gene networks: a novel approach in gene array profiling of myometrial events during guinea pig pregnancy. Am J Obstet Gynecol (2006) 1.50
Gaussian mixture clustering and imputation of microarray data. Bioinformatics (2004) 1.49
In silico repositioning of approved drugs for rare and neglected diseases. Drug Discov Today (2011) 1.45
An expiratory assist during spontaneous breathing can compensate for endotracheal tube resistance. Anesth Analg (2009) 1.41
Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors. Invest New Drugs (2009) 1.41
Camptothecins: a review of their chemotherapeutic potential. Drugs (2002) 1.40
Shape signatures: a new approach to computer-aided ligand- and receptor-based drug design. J Med Chem (2003) 1.39
Multi-level analysis of organic anion transporters 1, 3, and 6 reveals major differences in structural determinants of antiviral discrimination. J Biol Chem (2008) 1.38
POSITIVE TEST FOR ANTITHYROGLOBULIN ANTIBODIES DUE TO ADMINISTRATION OF IMMUNOGLOBULIN REPLACEMENT THERAPY IN A PATIENT WITH THYROID CANCER. Endocr Pract (2015) 1.38
Design, synthesis, cytoselective toxicity, structure-activity relationships, and pharmacophore of thiazolidinone derivatives targeting drug-resistant lung cancer cells. J Med Chem (2008) 1.37
Bile salts of vertebrates: structural variation and possible evolutionary significance. J Lipid Res (2009) 1.37
Surface acetylation of polyamidoamine (PAMAM) dendrimers decreases cytotoxicity while maintaining membrane permeability. Bioconjug Chem (2007) 1.36
A ligand-based approach to identify quantitative structure-activity relationships for the androgen receptor. J Med Chem (2004) 1.35
Microfabricated porous silicon particles enhance paracellular delivery of insulin across intestinal Caco-2 cell monolayers. Pharm Res (2003) 1.34
GLI1 regulates a novel neuropilin-2/α6β1 integrin based autocrine pathway that contributes to breast cancer initiation. EMBO Mol Med (2013) 1.33
Topology scanning and putative three-dimensional structure of the extracellular binding domains of the apical sodium-dependent bile acid transporter (SLC10A2). Biochemistry (2004) 1.33
Evolution and function of the NR1I nuclear hormone receptor subfamily (VDR, PXR, and CAR) with respect to metabolism of xenobiotics and endogenous compounds. Curr Drug Metab (2006) 1.32
In vitro and pharmacophore-based discovery of novel hPEPT1 inhibitors. Pharm Res (2005) 1.30
The phytoestrogen coumestrol is a naturally occurring antagonist of the human pregnane X receptor. Mol Endocrinol (2007) 1.29
Pharmacokinetics and safety of bortezomib in patients with advanced malignancies and varying degrees of liver dysfunction: phase I NCI Organ Dysfunction Working Group Study NCI-6432. Clin Cancer Res (2012) 1.27
Pregnane X receptor activation induces FGF19-dependent tumor aggressiveness in humans and mice. J Clin Invest (2011) 1.27
PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics. Pharmacogenomics (2008) 1.27
Endocytosis and interaction of poly (amidoamine) dendrimers with Caco-2 cells. Pharm Res (2007) 1.25
Structure-function analysis of barley NLR immune receptor MLA10 reveals its cell compartment specific activity in cell death and disease resistance. PLoS Pathog (2012) 1.25
Detecting hidden sequence propensity for amyloid fibril formation. Protein Sci (2004) 1.25
DNA microarray data imputation and significance analysis of differential expression. Bioinformatics (2005) 1.24
Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members. J Biol Chem (2007) 1.22
Molecular determinants of substrate/inhibitor binding to the human and rabbit renal organic cation transporters hOCT2 and rbOCT2. Mol Pharmacol (2005) 1.21
Endocytosis inhibitors prevent poly(amidoamine) dendrimer internalization and permeability across Caco-2 cells. Mol Pharm (2008) 1.21
New predictive models for blood-brain barrier permeability of drug-like molecules. Pharm Res (2008) 1.20
Notch1 co-opts lymphoid enhancer factor 1 for survival of murine T-cell lymphomas. Blood (2007) 1.18
Expanding the roles for pregnane X receptor in cancer: proliferation and drug resistance in ovarian cancer. Clin Cancer Res (2008) 1.18
The importance of discerning shape in molecular pharmacology. Trends Pharmacol Sci (2009) 1.17
Inhibition of influenza virus replication via small molecules that induce the formation of higher-order nucleoprotein oligomers. Proc Natl Acad Sci U S A (2011) 1.17
Functional evolution of the vitamin D and pregnane X receptors. BMC Evol Biol (2007) 1.17
Continuous production of lipase-catalyzed biodiesel in a packed-bed reactor: optimization and enzyme reuse study. J Biomed Biotechnol (2010) 1.16
Dose-escalating and pharmacologic study of oxaliplatin in adult cancer patients with impaired hepatic function: a National Cancer Institute Organ Dysfunction Working Group study. Clin Cancer Res (2007) 1.15
Pharmacophore-based discovery of ligands for drug transporters. Adv Drug Deliv Rev (2006) 1.15
DNA lesions induced by UV A1 and B radiation in human cells: comparative analyses in the overall genome and in the p53 tumor suppressor gene. Proc Natl Acad Sci U S A (2005) 1.15
In vitro and in vivo induction of cytochrome p450: a survey of the current practices and recommendations: a pharmaceutical research and manufacturers of america perspective. Drug Metab Dispos (2009) 1.15
Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug. Clin Pharmacokinet (2007) 1.14
Alleviation of gut inflammation by Cdx2/Pxr pathway in a mouse model of chemical colitis. PLoS One (2012) 1.14
Evolution of pharmacologic specificity in the pregnane X receptor. BMC Evol Biol (2008) 1.14
A comprehensive in vitro and in silico analysis of antibiotics that activate pregnane X receptor and induce CYP3A4 in liver and intestine. Drug Metab Dispos (2008) 1.14
Highly potent triazole-based tubulin polymerization inhibitors. J Med Chem (2007) 1.13
Current perspectives on the cellular uptake and trafficking of riboflavin. Adv Drug Deliv Rev (2003) 1.13
Activated pregnenolone X-receptor is a target for ketoconazole and its analogs. Clin Cancer Res (2007) 1.12
Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group. Semin Oncol (2003) 1.12
Using molecular similarity to highlight the challenges of routine immunoassay-based drug of abuse/toxicology screening in emergency medicine. BMC Emerg Med (2009) 1.12
The solute carrier family 10 (SLC10): beyond bile acid transport. Mol Aspects Med (2013) 1.11
Positive hepatitis B surface antigen tests due to recent vaccination: a persistent problem. BMC Clin Pathol (2012) 1.11
Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study. Clin Cancer Res (2002) 1.10
Bias in estimation of transporter kinetic parameters from overexpression systems: Interplay of transporter expression level and substrate affinity. J Pharmacol Exp Ther (2006) 1.10
Improved method for predicting beta-turn using support vector machine. Bioinformatics (2005) 1.10
Elucidating the 'Jekyll and Hyde' nature of PXR: the case for discovering antagonists or allosteric antagonists. Pharm Res (2009) 1.09
Evolving carbapenemases: can medicinal chemists advance one step ahead of the coming storm? J Med Chem (2010) 1.09
Evolution of the bile salt nuclear receptor FXR in vertebrates. J Lipid Res (2008) 1.08
Ligand specificity and evolution of liver X receptors. J Steroid Biochem Mol Biol (2008) 1.06
Pregnane xenobiotic receptor in cancer pathogenesis and therapeutic response. Cancer Lett (2012) 1.06
VEGF/neuropilin-2 regulation of Bmi-1 and consequent repression of IGF-IR define a novel mechanism of aggressive prostate cancer. Cancer Discov (2012) 1.06
Cellular entry of G3.5 poly (amido amine) dendrimers by clathrin- and dynamin-dependent endocytosis promotes tight junctional opening in intestinal epithelia. Pharm Res (2010) 1.04
Diversity of bile salts in fish and amphibians: evolution of a complex biochemical pathway. Physiol Biochem Zool (2010) 1.04
Efflux of depsipeptide FK228 (FR901228, NSC-630176) is mediated by P-glycoprotein and multidrug resistance-associated protein 1. J Pharmacol Exp Ther (2005) 1.04
Inhibition of human liver catechol-O-methyltransferase by tea catechins and their metabolites: structure-activity relationship and molecular-modeling studies. Biochem Pharmacol (2005) 1.04
Flavopiridol and trastuzumab synergistically inhibit proliferation of breast cancer cells: association with selective cooperative inhibition of cyclin D1-dependent kinase and Akt signaling pathways. Mol Cancer Ther (2002) 1.04